In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours
Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 5
Abstract
ABSTRACT Introduction: Globally, breast cancer persists a main cause of mortality. Because the number of possible drug combinations is basically unlimited, a strategy for the design of combination chemotherapy regimen of two anti-breast cancer drugs and determining the most promising combinations is crucial for improving the therapeutic outcomes and overcome the multi-therapeutic approach and holds the promise of delivering therapy to those in need. Aim: To assess the activity of combination of Doxorubicin and 5-fluorouracil on Human Breast Cancer Cell line (MCF-7). Materials and Methods: The cytotoxicity of Doxorubicin (DOX) and 5 fluorouracil (5FU) drugs or their combinations were evaluated by using 3-(4,5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium Bromide (MTT) viability assay against human breast cancer cell line MCF-7. Then, the combination effect proposed by Chou TC et al., based on IC50 values obtained from drugs alone and their combination was evaluated by Combination Index (CI) to determine the nature of synergism, antagonism and additivity action of drug combinations as: synergistic effect is recorded if CI <1, additive effect if CI=1, or antagonism if CI >1, the median-effect dose (Dm) also studied. Dose-Reduction Index (DRI) was also calculated to indicate the level of dose reduction for each drug in synergistic combination. Experiments were achieved with triplicate samples. The MTT assay data were expressed as mean±Standard Deviation (SD). The IC50 values for each drug were computed by GraphPad Prism 5.2 software (GraphPad Software Inc., USA). Dose-effect curve parameters, CI values, Fa-CI, DRI-Faplot were calculated by CompuSyn program. Results: The proliferation of MCF-7 cells was inhibited by 5 FU and DOX anti-cancer drugs in a dose-dependent effect. The DOX at (0.1) nM was antagonistic according to CI value which was 2.82283, while at (1) nM, the CI was 0.39429 that indicate strong synergistic action. Conclusion: This study confirmed the favourable effect of 5 FU in combination with DOX for treatment of breast cancer cell MCF-7 better than the single drug treatment.
Authors and Affiliations
Randa Mohammed Dhahi
Keywords
Related Articles
- EP ID EP585866
- DOI 10.7860/JCDR/2019/40273.12859
- Views 82
- Downloads 0
Translation, Cultural Adaptation and Validation of ACE III for Assessment of Cognition for Gujarati Population
ABSTRACT Introduction: Cognition is defined as “the mental action or process of acquiring knowledge and understanding through thought, experience, and the senses.” It is a method used by Central Nervous System (CNS) to p...
Imaging Diagnosis of Metastases to Breast: A Rare Presentation of Carcinoma Gallbladder
Breast metastases are extremely rare with a reported incidence of only 0.5-6.6% of all breast malignancies. We report a case of bilateral breast metastases in a 45-year-old lady who presented with an ulcero-proliferative...
Unusually High Serum Levels of CA 19-9 in an Ovarian Tumour: Malignant or Benign?
Carbohydrate antigen 19-9 (CA 19-9) is a tumour marker found to be elevated in some ovarian tumours. We share our experience with a 55-year-old postmenopausal lady with unusually high CA19-9 levels arising from a benign...
Significance of Platelet Volume Indices in STEMI Patients: A Case-Control Study
Introduction: Platelets have been well known contributors in the pathogenesis of cardiovascular disorders such as atherosclerosis and its complications such as acute Myocardial Infarction (MI). Aim: To study the changes...
Does Ear Morphology Establish Automatic Extraction of Soft Biometric Traits?
ABSTRACT Introduction: The external appearance of auricle varies between ethnic groups. However, there have been no studies on external ear morphometry correlating soft biometrics of the same individual. Therefore, a mor...